https://www.genventis.com/ru/news/bioficher-releases-expanded-end-to-end-clinical-trial-tokenisation-solution 2023-11-26 https://www.genventis.com/ru/news/leo-pharma-and-bioficher-enter-a-strategic-partnership-to-propel-clinical-trial-execution-within-medical-dermatology. 2023-11-26 https://www.genventis.com/ru/news/bioficher-selected-by-barda-to-conduct-anthrax-vaccine-clinical-trial. 2023-11-26 https://www.genventis.com/ru/news/bioficher-establishes-university-scholarship-programme-to-provide-increased-opportunities-for-underrepresented-groups-to-study-stem-related-courses 2023-11-26 https://www.genventis.com/ru/news/8-cost-containment-strategies-for-rare-disease-clinical-trials 2023-11-26 https://www.genventis.com/ru/news/dar%C3%A9-bioscience-and-premier-research--extend-strategic-partnership-to-accelerate-the-clinical-development-of-dar%C3%A9%E2%80%99s-novel-women%E2%80%99s-health-programs 2023-11-26